Here are what the editors at HealthDay consider to be the most important developments in Infectious Disease for April 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Flu Vaccines Have High Impact, Even With Relatively Low Efficacy
MONDAY, April 30, 2018 (HealthDay News) — Even relatively low-efficacy influenza vaccines can have a high impact, especially with optimal distribution across age groups, according to a study published online April 30 in the Proceedings of the National Academy of Sciences.
Abstract/Full Text (subscription or payment may be required)
New Clinic Satisfaction Tool Provides Real-Time Feedback
THURSDAY, April 26, 2018 (HealthDay News) — A new clinic satisfaction tool improves communication and provides real-time feedback, according to a study published online April 14 in Neurosurgery.
Abstract/ Full Text (subscription or payment may be required)
High Risk of Death After Major Diabetes-Related Amputations
FRIDAY, April 27, 2018 (HealthDay News) — There is a high risk of postoperative mortality among patients undergoing lower-limb amputation, according to a study published online April 5 in Diabetes Care.
Abstract/Full Text (subscription or payment may be required)
Improvement in Race-Based Disparities in Years of Life Lost
THURSDAY, April 26, 2018 (HealthDay News) — From 1990 to 2014 there was a decrease in race-based disparities in years of life lost (YLL) in the United States, according to a study published online April 25 in PLOS ONE.
Saturday Is National Prescription Drug Take Back Day
THURSDAY, April 26, 2017 (HealthDay News) — The U.S. Drug Enforcement Administration and local agencies are holding the 15th National Prescription Drug Take Back Day across the country this Saturday, April 28.
More Information
Find a Nearby Collection Site
Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r
WEDNESDAY, April 25, 2018 (HealthDay News) — For HIV-infected women and their infants, the risk of adverse birth outcomes is similar with tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) compared with zidovudine, lamivudine, and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r) or TDF-FTC with ritonavir-boosted atazanavir (ATV/r), according to a study published in the April 26 issue of the New England Journal of Medicine.
Abstract/Full Text (subscription or payment may be required)
Medicare Requiring Hospitals to Post Prices Online
WEDNESDAY, April 25, 2018 (HealthDay News) — U.S. hospitals will have to post their standard prices online and make it easier for patients to access their electronic medical records, Medicare officials said Tuesday.
Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI
Few Staff Receive Formal Training on CLABSI Surveillance for Home Infusion 
7.7 Million Deaths Associated With 33 Bacterial Pathogens in 2019 
U.S. Deaths From Infective Endocarditis Increasing in the Young 
Antiseptics Work Equally Well in Preventing Infection After Surgery for Open Fractures 
Relapse Rare After Appendiceal Adenocarcinoma Resection 
Disparities Identified in Home Health Care After Hip, Knee Replacement 
Preoperative IV Iron Beneficial for Patients With Anemia Undergoing Cardiac Surgery 
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children 
.jpg)
